FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response.	0.5							

_	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of	193
or Section 30(h) of the Investment Company Act of 1940	

1. Name and Address of Reporting Person* KARABELAS ARGERIS N					2. Issuer Name and Ticker or Trading Symbol REGENXBIO Inc. [RGNX]							elationship of the control of the co	able)		to Issu 0% Ow		
(Last)	(F GENXBIO	,	(Middle)		Date o		Trans	action (Montl	n/Day/Year)		Officer below)	(give title		ther (s elow)	pecify		
9804 MEDICAL CENTER DRIVE				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	ILLE M	ID	20850									X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	itate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			Transaction ate Month/Day/Y	Execution Date,		3. Transaction Code (Inst				5. Amour Securitie Beneficia Owned F Reported	s ally ollowing	6. Owners Form: Dire (D) or Indir (I) (Instr. 4)	ct c	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			1115(1.4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3) 1. Title of Conversion or Exercise Price of Derivative Security 2. 3. Transaction Date (Month/Day/Year)		3A. Deemed Execution Date if any (Month/Day/Ye	n Date, Transac Code (I		on of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Own Forn Dire or In (I) (II	ership n: ct (D) direct nstr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$35.52	06/04/2021		A		10,000		(1)	06/04/2031	Common Stock	10,000	\$0.00	10,000		D		

Explanation of Responses:

1. The option will vest in 12 equal monthly installments following June 4, 2021.

Remarks:

attorney-in-fact

06/08/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).